@RBR buyback is restricted to purchase at 5% greater than trailing 5 day average, so yesterday no shares could be purchased above 5.50 and today 5.8, tomorrow about 6. So at this rate the company won't get a look in.
Here's an article that warmed my heart. Link https://bnnbreaking.com/finance-nav/mayne-pharmas-strategic-shift-pays-off-a-look-into-their-mid-year-financial-triumph

Mayne Pharma's Strategic Shift Pays Off: A Look into Their Mid-YearFinancial Triumph

Mayne Pharma Group emerges as a beacon oftransformation and growth in the pharmaceutical industry. Withstrategic realignment, operational efficiencies, and key financialmilestones, the company sets a new standard for resilience andinnovation.

Asdawn breaks over the pharmaceutical horizon, a story oftransformation and resilience unfolds with Mayne Pharma Group at itscenter. In a recent financial discourse, the company’s executives,led by CFO Aaron Gray, painted a picture of a business on the brinkof a renaissance. This narrative is not just about numbers; it'sabout strategic shifts, operational efficiencies, and a dedication togrowth that is beginning to pay significant dividends.

Charting the Course of Change

In an era where the pharmaceutical industry faces relentlesspressure to innovate while managing costs, Mayne Pharma’s journeyover the first half of fiscal year 24 stands out. The companyreported a noteworthy $8 million positive underlying EBITDA,a testament to its strategic realignment and operational discipline.This financial milestone was underpinned by a $10 millioncost reduction, showcasing a leaner, more agile operationalmodel. Perhaps most compelling is the company’s projection ofpositive operating cash generation for the fiscalyear, a clear indicator of its turnaround efforts bearing fruit.

At the heart of this transformation is NEXTSTELLIS, Mayne Pharma’sflagship product in the Women's Health unit. Achieving a run ratebreakeven for NEXTSTELLIS is not just a financial win; it signifiesthe potential of Mayne Pharma’s pipeline and its ability to competein the competitive pharmaceutical landscape. The company’s U.S.Dermatology and Women's Health business units, in particular, havebeen stellar performers, contributing directly to an overall directcontribution of $40.6 million.

Investing in the Future

Behind the scenes of these impressive financial figures is a storyof careful investment and strategic foresight. Mayne Pharma has notshied away from investing in operational efficiency, a move that ispaying off in spades. This focus on operational andcommercial excellence is a clear signal that the company isnot just looking to survive but thrive. By recalibrating itsoperational model, Mayne Pharma is setting the stage for sustainablegrowth, a critical factor for long-term success in the pharmaceuticalindustry.

The investments extend beyond the balance sheet. Mayne Pharma isbetting on its people, processes, and technology to drive futuregrowth. This holistic approach to transformation is indicative of acompany that understands the complexities of the pharmaceuticallandscape and is prepared to navigate its challenges with innovationand agility.

A Balanced Perspective on Progress

While the financial achievements of Mayne Pharma in the first halfof fiscal year 24 are undeniably impressive, it's important to temperoptimism with a dose of caution. The pharmaceutical industry isnotoriously volatile, with regulatory hurdles, competitive pressures,and market dynamics posing constant challenges. Mayne Pharma’sjourney, while currently on an upward trajectory, will need tonavigate these uncertainties with the same strategic acumen it hasdemonstrated thus far.

Moreover, the company’s success hinges on its ability tomaintain momentum in operational and commercial excellence.Investments in efficiency and innovation must continue to yieldpositive results, and the company’s product pipeline, includingNEXTSTELLIS, must meet the high expectations set by both the companyand its stakeholders.

In conclusion, Mayne Pharma’s mid-year financial report is abeacon of hope not just for the company but for the industry atlarge. It showcases what is possible when a company combinesstrategic foresight with operational discipline. As Mayne Pharmacontinues on its transformative journey, it serves as a case study inresilience, innovation, and the relentless pursuit of growth.